Dr Simon Willis - Immunology division

Dr Simon Willis - Immunology division

Start Time: 
Wed, 13/10/2021 - 1:00pm
End Time: 
Wed, 13/10/2021 - 2:00pm

WEHI Wednesday Seminar hosted by Professor Stephen Nutt


Dr Simon Willis

Senior Research Officer - Nutt Lab, Immunology division - Infection, Inflammation & Immunity Theme, WEHI

Multiple Myeloma and IRF4: Understanding Addiction and Therapeutic opportunities

Join via TEAMS

Including Q&A session


Multiple myeloma (MM) is an incurable blood cancer where new treatment options are desperately needed. The transcription factor IRF4 is required for many aspects of the humoral immune response, including the development and survival of plasma cells (the myeloma cell of origin) that produce protective antibody. In 2008, an RNA interference screen established that IRF4 was also required for the survival of all MM cell lines examined, thus establishing IRF4 as possibly the best new drug target for both MM and antibody mediated autoimmune diseases. However, to date, no methods to inhibit IRF4 have been found, in part, due to a limited understanding of IRF4 biology.


In today’s seminar we will explore the transcriptional basis for IRF4 addiction in MM, what IRF4 itself needs to maintain MM survival and how we can leverage this information to move towards the development of new drugs to inhibit IRF4 function for MM treatment.


All welcome!